 |
|
|
| |
HIV-1 subtype (B or non-B) had no impact on the efficacy of B/F/TAF or resistance development in five phase 3 treatment-naïve or switch studies
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference, 23-27 July 2018, Amsterdam, Netherlands
RK Acosta1, KL White1, W Garner1, X Wei1, K Andreatta1, M Willkom1, C Kityo2, A Avihingsanon3, S Romanova4, F Maggiolo5, Y Yazdanpanah6, C Orkin7, J Rockstroh8, E DeJesus9, D SenGupta1, T Makadzange1, H Graham1, H Martin1, and E Quirk1
1Gilead Sciences, Foster City, California, United States, 2Joint Clinical Research Centre, Kampala, Uganda, 3Thai Red Cross AIDS Research Centre (HIV-NAT), Bangkok, Thailand, 4Center for Prevention and Treatment of AIDS and Infectious Diseases, Saint Petersburg, Russia, 5ASST Papa Giovanni XXIII - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy,6Groupe Hospitalier Bichat Claude Bernard, Paris, France, 7Barts Health NHS Trust, Royal London Hospital, Ambrose King Centre, London, United Kingdom, 8Universitätsklinikum Bonn, Bonn, Germany, 9Orlando Immunology Center, Orlando, Florida, United States
|
| |
|
|
|
|
|
